Hansa Biopharma announced that it plans to restructure the organisation to better align and focus on key clinical development and commercial priorities. The planned restructuring would result in an approximately 20-25% reduction in the current workforce and will result in approximately SEK 75-85 million in annual savings when implemented. The restructuring is subject to negotiation with relevant trade unions.

As part of the restructuring, Hansa will notify the Swedish Public Employment Service (Sw. Arbetsförmedlingen) and seek consultations with the trade unions regarding the reorganisation. Decisions regarding employee reductions will take place after the change consultations have been concluded according to local regulations.